talquetamab
janssen
['monumental-1', 'talquetamab']
watch this interview with prof. monique minnema, summarising the results of the clinical trial monumental-1, presented at #eha2023. the phase i/ii monumental-1 trial evaluates talquetamab in patients with relapsed/refractory myeloma. 
A network of highly efficient, effective and sustainable myeloma and AL amyloidosis patient organisations across Europe